Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Melanoma acral en población caucásica, Estudio de cohorte sobre factores epidemiológicos, clinicopatológicos y pronósticos, Acral Melanoma in the Caucasian Population

  • Angel-Baldo, J.
  • Podlipnik, Sebastian|||0000-0003-4150-0522
  • Azón, A.
  • Boada, Aram|||0000-0001-9809-5308
  • Arrieta, A.
  • Marcoval, Joaquim|||0000-0002-6489-1872
  • López Sánchez, Cristina|||0000-0003-1866-6989
  • Sàbat, M.
  • Segura, S.
  • Bodet, D.
  • Curcó, N.
  • Lopez-Castillo, D.
  • Solà, J.
  • Quintana-Codina, M.
  • Baliu-Piqué, C.
  • Just Sarobé, Miquel|||0000-0002-9649-9250
  • Martín-Sala, S.
  • Malvehy, J.
  • Puig, Susana|||0000-0003-1337-9745
  • Carrera, Caty|||0000-0002-0804-0969
  • Marti, R.M.
  • Matas-Nadal, C.
  • Soria-Gili, Xavier
  • Gatius, S.
  • Vilardell, Felip
  • Gil, I.
  • Grau, C.
  • Martínez, F.
  • Lobos, N.
  • Yélamos, Oriol|||0000-0002-8058-3095
  • Dalmau, J.
  • González-Cruz, C.|||0000-0003-0117-8858
  • Hilari, H.
  • Pasquali, P.
  • Sagristà, M.
  • Olivella-Garcés, M.R.
  • Bonfill-Ortí, Montserrat
  • Ramón Ferreres, J.
  • Jaka, A.
  • Quer, A.
  • Richarz, N.
  • Zarzoso Muñoz, I.
  • Zaballos, Pedro
  • Formigon, M.
  • Galvany, L.
  • Alegre, M.
  • Sánchez-Puigdollers, A.
  • Mohino-Farré, N.
  • Masferrer, E.
Introducción: El melanoma acral está asociado con un pronóstico desfavorable. El estudio sobre las características y el pronóstico en los pacientes caucásicos puede ser crucial para comprender las características distintivas de este tumor. Objetivos: Analizar las características epidemiológicas, clinicopatológicas y pronósticas del melanoma acral en los pacientes caucásicos. Material y métodos: Estudio de cohorte retrospectivo de melanoma acral a partir de una base de datos multi-institucional en 20 hospitales españoles, entre enero de 2000 y diciembre de 2019. Resultados: Se identificaron un total de 733 melanomas acrales (edad media: 67,5 años, el 95,2% caucásicos y el 77,5% en los pies). En general, el 77,5% de los casos fueron invasivos. Los melanomas localizados en los pies tuvieron una mayor proporción de casos invasivos (80,8 vs. 69,8%; p = 0,003), estadios III y IV al diagnóstico (24,8 vs. 11,7%; p < 0,001), valores de Breslow más altos (2,8 vs. 2,0 mm; p = 0,021) y una mayor tasa de positividad de biopsia selectiva del ganglio centinela (BSGC) (30,7 vs. 15,7%; p = 0,012). Un mayor grosor de Breslow y una edad de aparición más tardía fueron factores de riesgo para menor supervivencia específica por melanoma. Un mayor grosor de Breslow y la ulceración fueron los factores pronósticos independientes menor supervivencia libre de recaída. La localización del melanoma y el subtipo histopatológico no se asociaron con un peor pronóstico. Las recurrencias fueron frecuentes (27,7%), con a distancia apareciendo antes que las recurrencias locorregionales (1,32 años [IQR: 1,12-1,87] vs. 2,14 años [IQR: 1,68-2,70]; p = 0,015). Conclusión: Este estudio, el mayor en una población predominantemente caucásica, subraya los resultados desfavorables del melanoma acral. Los melanomas en los pies mostraron una detección tardía, mayor proporción de melanomas invasivos, valores de Breslow más profundos, mayor positividad o afectación de BSGC y estadios AJCC más altos. La alta tasa de recurrencia y las metástasis a distancia tempranas enfatizan el papel crítico del seguimiento intensivo y las pruebas de imagen rutinarias para detectar recaídas asintomáticas., Background: Acral melanoma is associated with poor prognosis. Studying the characteristics and prognosis of Caucasian patients is crucial to understand the distinct features of this tumor. Objectives: To analyze the epidemiological, clinicopathological, and prognostic features of acral melanoma in Caucasian patients. Methods: We conducted a retrospective, multicenter, cohort study of acral melanoma from a database across 20 hospitals from South Europe from January 2000 to December 2019. Results: A total of 733 acral melanomas were identified (median age, 67.5 years; 95.2%, Caucasians; 77.5% of which were located on the feet). Overall, 77.5% of cases were invasive melanomas. Foot melanomas had a higher proportion of invasive cases (80.8% vs 69.8%; p = 0.003), stages III and IV at diagnosis (24.8% vs 11.7%; p < 0.001), thicker Breslow depth (2.8 mm vs 2.0 mm; p = 0.021) and a higher rate of positive sentinel lymph node biopsy (SLNB) (30.7% vs 15.7%; p = 0.012). Thicker Breslow depth and later age of onset were risk factors for melanoma-specific survival. Thicker Breslow depth and ulceration were independent prognostic factors of relapse-free survival. Melanoma location and histopathological subtype were not associated with worse prognosis. Recurrences were a common finding (27.7%), with distant metastases appearing earlier than locoregional recurrences (1.32 years [IQR, 1.12-1.87] vs 2.14 years [IQR, 1.68-2.70]; p = 0.015). Conclusion: This study, the largest in a predominantly Caucasian population, underscores the unfavorable outcomes of acral melanoma. Foot melanomas exhibited delayed detection, increased invasiveness, thicker Breslow depth, increased SLNB involvement, and higher AJCC stages. The high recurrence rate and early distant metastases emphasize the critical role of intensive follow-up and routine imaging modalities to detect asymptomatic relapses.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma

  • Sanegre, Sabina
  • Eritja, Núria
  • Andrea, Carlos de
  • Díaz-Martín, Juan
  • Díaz-Lagares, Ángel
  • Jácome, M. A.
  • Salguero Aranda, Carmen
  • García-Ros, David
  • Davidson, Ben
  • López-López, Rafael
  • Melero, Ignacio
  • Navarro, Samuel
  • Ramón y Cajal, Santiago
  • Alava, Enrique de
  • Matias-Guiu, Xavier
  • Noguera, Rosa
[Abstract] The invasive tumor front (the tumor–host interface) is vitally important in malignant cell progression and metastasis. Tumor cell interactions with resident and infiltrating host cells and with the surrounding extracellular matrix and secreted factors ultimately determine the fate of the tumor. Herein we focus on the invasive tumor front, making an in-depth characterization of reticular fiber scaffolding, infiltrating immune cells, gene expression, and epigenetic profiles of classified aggressive primary uterine adenocarcinomas (24 patients) and leiomyosarcomas (11 patients). Sections of formalin-fixed samples before and after microdissection were scanned and studied. Reticular fiber architecture and immune cell infiltration were analyzed by automatized algorithms in colocalized regions of interest. Despite morphometric resemblance between reticular fibers and high presence of macrophages, we found some variance in other immune cell populations and distinctive gene expression and cell adhesion-related methylation signatures. Although no evident overall differences in immune response were detected at the gene expression and methylation level, impaired antimicrobial humoral response might be involved in uterine leiomyosarcoma spread. Similarities found at the invasive tumor front of uterine adenocarcinomas and leiomyosarcomas could facilitate the use of common biomarkers and therapies. Furthermore, molecular and architectural characterization of the invasive front of uterine malignancies may provide additional prognostic information beyond established prognostic factors., This research was supported by grants from the ISCIII and ERDF (PI17/01558 and PI20/01107), by the CIBERONC (contracts CB16/12/00484, CB16/12/0328, CB16/12/00363, CB16/12/00364, CB16/12/00481, and CB16/12/00231) and Grupos Coordinados Estables from the Asociación Española Contra el Cáncer (AECC). ÁD-L was funded by a contract “Juan Rodés” from the ISCIII (JR17/00016).
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer

  • Gatius Calderó, Sònia
  • Jové Font, Mariona
  • Megino-Luque, Cristina
  • Albertí Valls, Manel
  • Yeramian Hakim, Andree
  • Bonifaci, Núria
  • Pinyol, Miquel
  • Santacana Espasa, Maria
  • Pradas Barriga, Irene
  • Llobet Navàs, David
  • Pamplona Gras, Reinald
  • Matias-Guiu, Xavier
  • Eritja Sánchez, Núria
Metabolomic profiling analysis has the potential to highlight new molecules and cellular pathways that may serve as potential therapeutic targets for disease treatment. In this study, we used an LC-MS/MS platform to define, for the first time, the specific metabolomic signature of uterine serous carcinoma (SC), a relatively rare and aggressive variant of endometrial cancer (EC) responsible for 40% of all endometrial cancer-related deaths. A metabolomic analysis of 31 ECs (20 endometrial endometrioid carcinomas (EECs) and 11 SCs) was performed. Following multivariate statistical analysis, we identified 232 statistically different metabolites among the SC and EEC patient samples. Notably, most of the metabolites identified (89.2%) were lipid species and showed lower levels in SCs when compared to EECs. In addition to lipids, we also documented metabolites belonging to amino acids and purine nucleotides (such as 2-Oxo-4-methylthiobutanoic acid, synthesised by acireductone dioxygenase 1 (ADI1) enzyme), which showed higher levels in SCs. To further investigate the role of ADI1 in SC, we analysed the expression protein levels of ADI1 in 96 ECs (67 EECs and 29 SCs), proving that the levels of ADI1 were higher in SCs compared to EECs. We also found that ADI1 mRNA levels were higher in p53 abnormal ECs compared to p53 wild type tumours. Furthermore, elevated ADI1 mRNA levels showed a statistically significant negative correlation with overall survival and progression-free survival among EEC patients. Finally, we tested the ability of ADI1 to induce migration and invasion capabilities in EC cell lines. Altogether, these results suggest that ADI1 could be a potential therapeutic target in poor-prognosis SCs and other Ecs with abnormal p53 expression., This study was funded by the Instituto de Salud Carlos III (ISCIII) through projects PI20/00502, CP19/00025, CB16/12/00231, PI16/00692, PI18/00573, PI21/00672, CP17/00063 and PI18/00795; and by the Spanish Ministry of Science, Innovation and Universities (Ministerio de Ciencia, Innovación y Universidades, RTI2018-099200-BI00), co-funded by the European Regional Development Fund (ERDF) as part of the “A way to make Europe” programme and the European Social Fund (ESF) as part of the “Investing in Your Future” programme. This study was also supported by the “Xarxa de Bancs de Tumors de Catalunya” and sponsored by “Pla Director d’Oncologia de Catalunya (XBTC)”, “IRBLleida Biobank” (B.0000682) and “Plataforma Biobancos” PT20/00021. We also thank the Generalitat of Catalonia: Agency for Management of University and Research Grants (2017SGR1368 and 2017SGR696) and the “Asociación Española Contra el Cáncer” (AECC; Grupos Estables 2018 and LABAE19004LLOB). M.J. is a Serra Húnter Fellow. N.E. (MS19/00025) and D.L-N. (MS17/00063) are recipients of a Miguel Servet research scheme (co-funded by the ESF program “Investing in Your Future”). C. M-L. holds a predoctoral fellowship from the Generalitat de Catalunya (2020FI_B2 00099) and the predoctoral fellowship “Ajuts 2021 de Promoció de la Recerca en Salut-9a edició” from IRBLleida/Diputació de Lleida. IRBLleida is a CERCA Program/Generalitat of Catalonia.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer

  • Roman-Canal, Berta
  • Gatius, Sònia
  • Bonnin, Sarah
  • Ruiz-Miró, Maria
  • González, Esperanza
  • Gil Moreno, Antonio
  • Colas Ortega, Eva
  • Moiola, Cristian Pablo
Taqman OpenArray technology; Lung cancer diagnosis; Biomarkers, Tecnología Taqman OpenArray; Diagnóstico de cáncer de pulmón; Biomarcadores, Tecnologia Taqman OpenArray; Diagnòstic del càncer de pulmó; Biomarcadors, Lung cancer is the leading cause of cancer-related deaths among men and women in the world, accounting for the 25% of cancer mortality. Early diagnosis is an unmet clinical issue. In this work, we focused to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the pleural lavage, a proximal fluid in lung cancer patients, as a source of potential biomarkers. We isolated EVs by ultracentrifuge method from 25 control pleural fluids and 21 pleural lavages from lung cancer patients. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 288 out of the 754 miRNAs that were contained in the OpenArray. The differential expression analysis yielded a list of 14 miRNAs that were significantly dysregulated (adj. p-value < 0.05 and logFC lower or higher than 3). Using Machine Learning approach we discovered the lung cancer diagnostic biomarkers; miRNA-1-3p, miRNA-144-5p and miRNA-150-5p were found to be the best by accuracy. Accordance with our finding, these miRNAs have been related to cancer processes in previous studies. This results opens the avenue to the use of EV-associated miRNA of pleural fluids and lavages as an untapped source of biomarkers, and specifically, identifies miRNA-1-3p, miRNA-144-5p and miRNA 150-5p as promising biomarkers of lung cancer diagnosis., The sample collection was supported by IRBLleida BIOBANK (B.0000682) and Plataforma biobancos PT17/0015/0027.EC hold a postdoctoral fellowship from the Departament de Salut of the Generalitat de Catalunya (SLT002/16/00274). This study was supported by: “Discovery, validation and implementation of biomarkers for Precision Oncology” (ISCIII PIE15/00029), CIBERONC (CB16/12/00231 and CB16/12/00328), Grups consolidats de la Generalitat de Catalunya (2017SGR1368 and 2017SGR1661) and Asociación Española contra el Cancer (GCTRA1804MATI).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer

  • Gatius Calderó, Sònia
  • Jové Font, Mariona
  • Megino-Luque, Cristina
  • Albertí Valls, Manel
  • Yeramian Hakim, Andree
  • Bonifaci, Núria
  • Pinyol, Miquel
  • Santacana Espasa, Maria
  • Pradas Barriga, Irene
  • Llobet Navàs, David
  • Pamplona Gras, Reinald
  • Matias-Guiu, Xavier
  • Eritja Sánchez, Núria
Metabolomic profiling analysis has the potential to highlight new molecules and cellular pathways that may serve as potential therapeutic targets for disease treatment. In this study, we used an LC-MS/MS platform to define, for the first time, the specific metabolomic signature of uterine serous carcinoma (SC), a relatively rare and aggressive variant of endometrial cancer (EC) responsible for 40% of all endometrial cancer-related deaths. A metabolomic analysis of 31 ECs (20 endometrial endometrioid carcinomas (EECs) and 11 SCs) was performed. Following multivariate statistical analysis, we identified 232 statistically different metabolites among the SC and EEC patient samples. Notably, most of the metabolites identified (89.2%) were lipid species and showed lower levels in SCs when compared to EECs. In addition to lipids, we also documented metabolites belonging to amino acids and purine nucleotides (such as 2-Oxo-4-methylthiobutanoic acid, synthesised by acireductone dioxygenase 1 (ADI1) enzyme), which showed higher levels in SCs. To further investigate the role of ADI1 in SC, we analysed the expression protein levels of ADI1 in 96 ECs (67 EECs and 29 SCs), proving that the levels of ADI1 were higher in SCs compared to EECs. We also found that ADI1 mRNA levels were higher in p53 abnormal ECs compared to p53 wild type tumours. Furthermore, elevated ADI1 mRNA levels showed a statistically significant negative correlation with overall survival and progression-free survival among EEC patients. Finally, we tested the ability of ADI1 to induce migration and invasion capabilities in EC cell lines. Altogether, these results suggest that ADI1 could be a potential therapeutic target in poor-prognosis SCs and other Ecs with abnormal p53 expression., This study was funded by the Instituto de Salud Carlos III (ISCIII) through projects PI20/00502, CP19/00025, CB16/12/00231, PI16/00692, PI18/00573, PI21/00672, CP17/00063 and PI18/00795; and by the Spanish Ministry of Science, Innovation and Universities (Ministerio de Ciencia, Innovación y Universidades, RTI2018-099200-BI00), co-funded by the European Regional Development Fund (ERDF) as part of the “A way to make Europe” programme and the European Social Fund (ESF) as part of the “Investing in Your Future” programme. This study was also supported by the “Xarxa de Bancs de Tumors de Catalunya” and sponsored by “Pla Director d’Oncologia de Catalunya (XBTC)”, “IRBLleida Biobank” (B.0000682) and “Plataforma Biobancos” PT20/00021. We also thank the Generalitat of Catalonia: Agency for Management of University and Research Grants (2017SGR1368 and 2017SGR696) and the “Asociación Española Contra el Cáncer” (AECC; Grupos Estables 2018 and LABAE19004LLOB). M.J. is a Serra Húnter Fellow. N.E. (MS19/00025) and D.L-N. (MS17/00063) are recipients of a Miguel Servet research scheme (co-funded by the ESF program “Investing in Your Future”). C. M-L. holds a predoctoral fellowship from the Generalitat de Catalunya (2020FI_B2 00099) and the predoctoral fellowship “Ajuts 2021 de Promoció de la Recerca en Salut-9a edició” from IRBLleida/Diputació de Lleida. IRBLleida is a CERCA Program/Generalitat of Catalonia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence of Melanoma in Catalonia, Spain, Is Rapidly Increasing in the Elderly Population. A Multicentric Cohort Study

  • Podlipnik, Sebastian|||0000-0003-4150-0522
  • Carrera, Cristina|||0000-0003-1608-8820
  • Boada, Aram|||0000-0001-9809-5308
  • Richarz, Nina
  • Marcoval, Joaquim|||0000-0002-6489-1872
  • Ferreres, Josep Ramón
  • Bodet, Domingo|||0000-0003-2227-0696
  • Martí, Rosa María|||0000-0001-6866-6114
  • Segura, Sonia|||0000-0003-0653-1382
  • Sabat Santandreu, Mireia|||0000-0003-2583-5138
  • Dalmau-Arias, Joan
  • Quintana, Mònica
  • Azon, Antoni|||0000-0003-3112-552X
  • Curcó, Neus
  • Formigon, Manel
  • Olivella-Garcés, María Rosa
  • Zaballos, Pedro
  • Sola, Joaquim
  • Galvany, Loida
  • Baliu-Piqué, Carola
  • Alegre Fernández, Marta|||0000-0003-4718-4831
  • Pasquali, Paola
  • Malvehy, Josep|||0000-0002-6998-914X
  • Puig, Susana|||0000-0003-1337-9745
The incidence of melanoma has been increasing worldwide during recent decades. The objective of the study was to analyse the trends in incidence for in situ and invasive melanoma in the Spanish region of Catalonia during the period of 2008-2017. We designed a cross-sectional study with an age-period-cohort analysis of melanoma patient data from the Network of Melanoma Centres in Catalonia. Our database covered a population of over seven million and included a total of 8626 patients with incident melanoma. The main outcome measures were crude and age-standardised incidence rates to the European 2013 standard population. Joinpoint regression models were used to evaluate the population trends. We observed an increase in the age-standardised incidence rate (per 100,000 population) of all melanoma subtypes from 11.56 in 2008 to 13.78 in 2017 with an average annual percent change (AAPC) of 3.5%. This incidence increase was seen exclusively in the older population. Moreover, the stratified analysis showed a statistically significant increase in the age-standardised incidence rate for invasive (AAPC 2.1%) and in situ melanoma (AAPC 6.5%). In conclusion, the incidence of melanoma has continued to increase in the elderly population over recent decades, with a rapidly increasing trend of in situ melanomas and the lentigo maligna subtype.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

  • Gámez-Chiachio, Manuel
  • Molina-Crespo, Ángela
  • Ramos-Nebot, Carmen
  • Martinez-Val, Jeannette
  • Martinez, Lidia
  • Gassner, Katja
  • Llobet, Francisco J.
  • Soriano, Mario
  • Hernandez, Alberto
  • Cordani, Marco
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Diaz, Eva
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Triviño, Juan Carlos
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Rodríguez-Barrueco, Ruth|||0000-0003-4925-8865
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Llobet Navas, David|||0000-0003-1443-7003
  • Sarrió, David
  • Moreno-Bueno, Gema
Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel effective targeted treatments for HER2/GSDMB aggressive tumors. Different in vitro approaches (immunoblot, qRT-PCR, flow cytometry, proteomic analysis, immunoprecipitation, and confocal/electron microscopy) were performed in HER2 breast and gastroesophageal carcinoma cell models. Results were then validated using in vivo preclinical animal models and analyzing human breast and gastric cancer samples. GSDMB up-regulation renders HER2 cancer cells more resistant to anti-HER2 agents by promoting protective autophagy. Accordingly, the combination of lapatinib with the autophagy inhibitor chloroquine increases the therapeutic response of GSDMB-positive cancers in vitro and in zebrafish and mice tumor xenograft in vivo models. Mechanistically, GSDMB N-terminal domain interacts with the key components of the autophagy machinery LC3B and Rab7, facilitating the Rab7 activation during pro-survival autophagy in response to anti-HER2 therapies. Finally, we validated these results in clinical samples where GSDMB/Rab7/LC3B co-expression associates significantly with relapse in HER2 breast and gastric cancers. Our findings uncover for the first time a functional link between GSDMB over-expression and protective autophagy in response to HER2-targeted therapies. GSDMB behaves like an autophagy adaptor and plays a pivotal role in modulating autophagosome maturation through Rab7 activation. Finally, our results provide a new and accessible therapeutic approach for HER2/GSDMB + cancers with adverse clinical outcome. The online version contains supplementary material available at 10.1186/s13046-022-02497-w.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness

  • Sonzini, Giorgia
  • Granados-Aparici, Sofia
  • Sanegre, Sabina
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
  • Diaz-Martin, Juan
  • de Andrea, Carlos
  • Eritja, Núria
  • Bao Caamano, Aida
  • Costa-Fraga, Nicolás|||0000-0002-0869-8509
  • García-Ros, David
  • Salguero-Aranda, Carmen
  • Davidson, Ben
  • López-López, Rafael|||0000-0002-2240-6277
  • Melero, Ignacio|||0000-0002-1360-348X
  • Navarro, Samuel
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • De Álava, Enrique|||0000-0001-8400-046X
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Noguera, Rosa
The incidence of new cancer cases is expected to increase significantly in the future, posing a worldwide problem. In this regard, precision oncology and its diagnostic tools are essential for developing personalized cancer treatments. Digital pathology (DP) is a particularly key strategy to study the interactions of tumor cells and the tumor microenvironment (TME), which play a crucial role in tumor initiation, progression and metastasis. The purpose of this study was to integrate data on the digital patterns of reticulin fiber scaffolding and the immune cell infiltrate, transcriptomic and epigenetic profiles in aggressive uterine adenocarcinoma (uADC), uterine leiomyosarcoma (uLMS) and their respective lung metastases, with the aim of obtaining key TME biomarkers that can help improve metastatic prediction and shed light on potential therapeutic targets. Automatized algorithms were used to analyze reticulin fiber architecture and immune infiltration in colocalized regions of interest (ROIs) of 133 invasive tumor front (ITF), 89 tumor niches and 70 target tissues in a total of six paired samples of uADC and nine of uLMS. Microdissected tissue from the ITF was employed for transcriptomic and epigenetic studies in primary and metastatic tumors. Reticulin fiber scaffolding was characterized by a large and loose reticular fiber network in uADC, while dense bundles were found in uLMS. Notably, more similarities between reticulin fibers were observed in paired uLMS then paired uADCs. Transcriptomic and multiplex immunofluorescence-based immune profiling showed a higher abundance of T and B cells in primary tumor and in metastatic uADC than uLMS. Moreover, the epigenetic signature of paired samples in uADCs showed more differences than paired samples in uLMS. Some epigenetic variation was also found between the ITF of metastatic uADC and uLMS. Altogether, our data suggest a correlation between morphological and molecular changes at the ITF and the degree of aggressiveness. The use of DP tools for characterizing reticulin scaffolding and immune cell infiltration at the ITF in paired samples together with information provided by omics analyses in a large cohort will hopefully help validate novel biomarkers of tumor aggressiveness, develop new drugs and improve patient quality of life in a much more efficient way.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

EV-associated miRNAs from pleural lavage as potential diagnostic biomarkers in lung cancer

  • Roman-Canal, Berta
  • Gatius, Sònia
  • Bonnin, Sarah
  • Ruiz-Miró, Maria
  • González, Esperanza
  • Gil Moreno, Antonio
  • Colas Ortega, Eva
  • Moiola, Cristian Pablo
Taqman OpenArray technology; Lung cancer diagnosis; Biomarkers, Tecnología Taqman OpenArray; Diagnóstico de cáncer de pulmón; Biomarcadores, Tecnologia Taqman OpenArray; Diagnòstic del càncer de pulmó; Biomarcadors, Lung cancer is the leading cause of cancer-related deaths among men and women in the world, accounting for the 25% of cancer mortality. Early diagnosis is an unmet clinical issue. In this work, we focused to develop a novel approach to identify highly sensitive and specific biomarkers by investigating the use of extracellular vesicles (EVs) isolated from the pleural lavage, a proximal fluid in lung cancer patients, as a source of potential biomarkers. We isolated EVs by ultracentrifuge method from 25 control pleural fluids and 21 pleural lavages from lung cancer patients. Analysis of the expression of EV-associated miRNAs was performed using Taqman OpenArray technology through which we could detect 288 out of the 754 miRNAs that were contained in the OpenArray. The differential expression analysis yielded a list of 14 miRNAs that were significantly dysregulated (adj. p-value < 0.05 and logFC lower or higher than 3). Using Machine Learning approach we discovered the lung cancer diagnostic biomarkers; miRNA-1-3p, miRNA-144-5p and miRNA-150-5p were found to be the best by accuracy. Accordance with our finding, these miRNAs have been related to cancer processes in previous studies. This results opens the avenue to the use of EV-associated miRNA of pleural fluids and lavages as an untapped source of biomarkers, and specifically, identifies miRNA-1-3p, miRNA-144-5p and miRNA 150-5p as promising biomarkers of lung cancer diagnosis., The sample collection was supported by IRBLleida BIOBANK (B.0000682) and Plataforma biobancos PT17/0015/0027.EC hold a postdoctoral fellowship from the Departament de Salut of the Generalitat de Catalunya (SLT002/16/00274). This study was supported by: “Discovery, validation and implementation of biomarkers for Precision Oncology” (ISCIII PIE15/00029), CIBERONC (CB16/12/00231 and CB16/12/00328), Grups consolidats de la Generalitat de Catalunya (2017SGR1368 and 2017SGR1661) and Asociación Española contra el Cancer (GCTRA1804MATI).